This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Chembio Announces Oral Presentation And Multiple Poster Presentations At 2012 HIV Diagnostics Conference

MEDFORD, N.Y., Dec. 13, 2012 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI),a leader in point-of-care diagnostic tests for infectious diseases, announces that an oral presentation and multiple poster presentations underscoring the clinical utility of the Company's Dual Path Platform ® rapid, point-of-care (POC) diagnostic tests are being presented at the 2012 HIV Diagnostics Conference being held December 12-14 at the Sheraton Atlanta Hotel.

An oral presentation entitled "Performance Evaluation of the DPP® HIV-SYPHILIS Assay: a novel, point-of-care rapid HIV 1/2, and Syphilis Treponema pallidum Antibody Combination Test" was delivered by Javan Esfandiari, Senior Vice President of Research and Development for Chembio. The presentation was made in conjunction with the "Testing for HIV/Hepatitis or HIV/Syphilis Co-infections" workshop moderated by Kelly Wroblewski, Association of Public Health Laboratories, which took place at 4:00 p.m. local time on December 12 th

In his presentation on Wednesday, Mr. Esfandiari showcased the Company's DPP ® HIV-SYPHILIS, a single-use immunochromatographic, rapid screening test for the detection of antibodies to HIV 1/2 and Syphilis Treponema pallidum in fingerstick whole blood, venous whole blood, serum or plasma. Data have shown the test to have accurate results with documented sensitivity and specificity for both HIV 1/2 and Syphilis antibodies on one device. 

Mr. Esfandiari noted, "In the U.S., approximately 16% of patients, as well as 28% of men, who are infected with syphilis are also co-infected with HIV. As a result, there is growing interest in an accurate, rapid POC test that can diagnose both HIV and syphilis antibodies. Moreover, syphilis facilitates HIV transmission, making an early and accurate syphilis diagnosis key to preventing continued transmission of both diseases. DPP ® HIV-SYPHILIS requires minimal patient sample and provides actionable results in 20 minutes, allowing for results and counseling at the point-of-care. Based on the market need and the strength of these data, we intend to work with the regulatory authorities to establish a pathway to approval for this much-needed diagnostic."  

In addition, the Company has two posters being presented at the Conference today: 
  • "Performance Evaluation of a Novel HIV-1/2 Rapid Test for the Detection of HIV-1/2 Antibodies in Oral Fluid and Whole Blood," which demonstrated the diagnostic sensitivity of the DPP ® HIV assay to detect HIV infection, currently pending FDA Pre-Marketing Application approval in point estimates ranging from 99.9% to 100% for fingerstick whole-blood specimens and 98.9% to 100% for oral-fluid specimens. The diagnostic specificity of the DPP ® HIV tests was 100% in all sites for fingerstick whole-blood specimens and 99.9% to 100% for oral-fluid specimens. The sensitivity estimate on oral-fluid specimens was lower in the United States (98.9%) compared with Mozambique and Nigeria (100%) mainly due to the known HIV-positive population. Approximately 84% (731/868) in the United States and 60% (129/215) in Nigeria of the known HIV-positive population recruited were taking antiretroviral drug therapy.  
  • "Evaluation of the DPP® HIV-HCV-Syphilis Assay: a novel, point-of-care rapid HIV 1/2, HCV and Syphilis Treponema pallidum Antibody Combination Test," which indicated that DPP ® HIV-HCV-Syphilis assay, a rapid, qualitative multiplex POC test for the detection of antibodies to HIV 1/2, HCV and Syphilis Treponema pallidum in fingerstick whole blood, venous whole blood, serum or plasma, can be used to screen for HIV, HCV and Syphilis Treponema pallidum antibodies. Compared with the FDA-approved HIV, HCV and Syphilis Treponemal tests, all selected blood, sera and plasma samples tested with DPP HIV-HCV-Syphilis assay had 100% specificity for HIV and Syphilis Treponemal bands, and 100% and 99.4% specificity with blood and sera/plasma for HCV band, respectively.

"We are delighted to have this solid body of clinical data presented at the 2012 HIV Diagnostics Conference including the outstanding performance of our HIV 1/2 test that is pending approval ," stated Lawrence Siebert, Chembio's Chief Executive Officer. "These data confirm the high sensitivity and specificity of our DPP ® rapid assays in patients with HIV and HIV-related infectious diseases. The simultaneous detection of multiple antibodies offers the opportunity to increase diagnosis of and treatment for these highly infectious diseases, which is hoped to reduce their transmission. As a result, there continues to be a substantial interest in these products by public health groups in the U.S. and abroad."

About the 2012 HIV Diagnostics Conference

The 2012 HIV Diagnostics Conference, co-sponsored by the Centers for Disease Control and Prevention (CDC), the National Minority AIDS Council (NMAC), and the Association of Public Health Laboratories (APHL), provides an opportunity for clinicians, clinical and public health laboratorians, HIV/AIDS program managers and directors, and industry representatives to review developments in HIV diagnostics, share data and research findings, and establish collaborations. Since its inception in 2005, the HIV Diagnostics Conference has served as an opportunity for those interested in issues related to HIV diagnostic testing to gather and discuss new developments and related prevention and surveillance measures.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 0.00%
FB $118.06 0.00%
GOOG $695.70 0.00%
TSLA $222.56 0.00%
YHOO $36.00 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs